Results 211 to 220 of about 27,357 (285)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Additional file 1 of A review of PI3K/AKT/mTOR inhibitors from traditional Chinese medicine: potential and perspective for activated phosphoinositide 3-kinase δ syndrome

Yixuan Xie, Linghui Nie, Litao Bai, Xiaodong Zhao   +3 more
openalex   +2 more sources

Distinct impact of PI(4)P flux on PI(4,5)P₂ steady states and oscillations. [PDF]

Proc Natl Acad Sci U S A
Xǔ XJ, Tong CS, Wu M.
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Toward a molecular logic of lipid droplet heterogeneity? [PDF]

Proc Natl Acad Sci U S A
Vanni S.
europepmc   +1 more source

Identification of a component of the tubulin poly-glutamylase complex required for phosphoinositide homeostasis and cilium assembly and maintenance [PDF]

Binshad Badarudeen, Loren Collado, Hung-Ju Chiang, Lei Wang, Irma Sánchez, Brian David Dynlacht   +5 more
openalex   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Metabolic control of cellular reprogramming: phospholipid remodeling tunes auxin signaling. [PDF]

Plant Cell
Wang J, Hu D.
europepmc   +1 more source

Lipid transfer proteins and PI4KIIα initiate nuclear p53-phosphoinositide signaling [PDF]

Noah D. Carrillo, Mo Chen, Poorwa Awasthi, Tianmu Wen, Xue Yang, Colin Sterling, Dhruv Brahmbhatt, Vincent L. Cryns, Richard A. Anderson   +8 more
openalex   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source